Contents

Search

amyloid-beta peptide 40 in plasma

Indications: - acute coronary syndrome - NSTEMI [1] Clinical significance: - predicts mortality in patients with acute coronary syndrome & NSTEMI [1] - each standard deviation increase in plasma Abeta40 (67 pg/mL) at midlife associated with 15% higher risk of mild cognitive impairment or dementia 25 years later [2]

Related

A4 amyloid peptide; beta-peptide

General

amyloid-beta peptide in plasma

References

  1. Stamatelopoulos K, Mueller-Hennessen K, Georgiopoulos G. Amyloid-beta (1-40) and Mortality in Patients With Non-ST- Segment Elevation Acute Coronary Syndrome: A Cohort Study. Ann Intern Med. 2018. May 22 PMID: 29799975 http://annals.org/aim/article-abstract/2681795/amyloid-1-40-mortality-patients-non-st-segment-elevation-acute
  2. George J Midlife Blood Amyloid Levels Tied to Late-Life Dementia. Plasma biomarker may predict Alzheimer's s progression decades before symptoms appear. MedPage Today August 5, 2021 https://www.medpagetoday.com/neurology/alzheimersdisease/93919 - Sullivan KJ, Blackshear C, Simino J et al Association of Midlife Plasma Amyloid-beta Levels With Cognitive Impairment in Late Life: The ARIC Neurocognitive Study. Neurology. 2921 Aug 4 PMID: 34349010 https://n.neurology.org/content/early/2021/08/04/WNL.0000000000012482

Component-of

amyloid-beta peptide 40/42 in plasma